TSHA
$4.40-0.16 (-3.51%)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Recent News
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story
Taysha Gene Therapies recently reported full-year 2025 results, with sales of US$9.77 million and a net loss of US$109 million, while also highlighting progress on TSHA-102 for Rett syndrome and receiving FDA Breakthrough Therapy designation. The company’s preparation for potential commercialization, including the hiring of veteran market access executive Brad Martin and alignment with the FDA on pivotal trial designs, underscores how seriously it is positioning TSHA-102 for a future...
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
Taysha Gene Therapies Inc (TSHA) reports a robust cash runway into 2028 and positive Phase I/II data for TSHA-102, despite increased expenses and net loss.
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary
Moby summary of Taysha Gene Therapies, Inc.'s Q4 2025 earnings call
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company’s March 19 conference call. TS
Taysha (TSHA) Q4 2025 Earnings Call Transcript
Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. This call may also contain forward-looking statements relating to Taysha Gene Therapies, Inc.'s growth, forecast cash runway and future operating results, discovery and development of product candidates, strategic alliances, and intellectual property, as well as matters that are not historical facts or information.